Clinical Trial

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Study acronym: TEN
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-31.
Trial Details
NCT Number NCT06119490
Lead Sponsor Peng Zhang
Conditions Toxic Epidermal Necrolysis
Enrollment 30 participants
Start Date 2023-07-05
Primary Completion 2026-07 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2023-11-28